Stock Events

Stock Events

Equillium 

$2.24
44
+$0.00+0% Friday 14:46

Statistics

Day High
2.27
Day Low
2.24
52W High
3.12
52W Low
0.49
Volume
0
Avg. Volume
2,796
Mkt Cap
142.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 8
$0.69
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.34
-0.24
-0.14
-0.04
Expected EPS
-0.05
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-22.4MNet Income

Analyst Ratings

11.00Average Price Target
The highest estimate is 20.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A4D.LSE. It's not an investment recommendation.
Apple
8
AAPL
NVIDIA
8
NVDA
Microsoft
7
MSFT
Amazon
7
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences operates in the biopharmaceutical field focusing on antiviral drugs, cancer, and inflammatory and respiratory diseases, overlapping with Equillium's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals specializes in medicines for eye diseases, allergic and inflammatory diseases, cancer, and cardiovascular and metabolic diseases, competing in the immunology space.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on human therapeutics in areas including cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation, competing with Equillium in the biologic drug market.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie operates in areas such as immunology, oncology, virology, and neuroscience, directly competing with Equillium in the development of treatments for autoimmune and inflammatory diseases.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases, including those in immunology and oncology, areas that overlap with Equillium's interests.
Novartis
NVS
Mkt Cap304.1B
Novartis focuses on a broad range of healthcare areas including advanced therapy platforms and immunology, which competes with Equillium's work on immune modulation therapies.
Pfizer
PFE
Mkt Cap162.16B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology and inflammation, making it a competitor in the same therapeutic areas as Equillium.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for a broad range of health conditions, including autoimmune diseases, directly competing with Equillium's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases such as cystic fibrosis and other serious diseases, including efforts in immunology, which could compete with Equillium's therapeutic approach.

About

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Show more...
CEO
Bruce D. Steel
Employees
14
Country
United States
ISIN
US29446K1060
WKN
000A2N7B3

Listings

STU
DE
0FY.STU
LSE
GB
0A4D.LSE
MU
DE
0FY.MU
F
DE
0FY.F

0 Comments

Share your thoughts

FAQ

What is Equillium stock price today?▼
The current price of 0A4D.LSE is $2.24 USD — it has increased by +0% in the past 24 hours. Watch Equillium stock price performance more closely on the chart.
What is Equillium stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Equillium stocks are traded under the ticker 0A4D.LSE.
Is Equillium stock price growing?▼
0A4D.LSE stock has risen by +1.73% compared to the previous week, the month change is a +6.67% rise, over the last year Equillium has showed a +18.64% increase.
What is Equillium market cap?▼
Today Equillium has the market capitalization of 142.03M
When is the next Equillium earnings date?▼
Equillium is going to release the next earnings report on November 18, 2026.
What were Equillium earnings last quarter?▼
0A4D.LSE earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.05 USD resulting in a +25.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Equillium revenue for the last year?▼
Equillium revenue for the last year amounts to 0 USD.
What is Equillium net income for the last year?▼
0A4D.LSE net income for the last year is -22.4M USD.
Does Equillium pay dividends?▼
Yes, 0A4D.LSE dividends are paid annual. The last dividend per share was 0.69 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Equillium have?▼
As of September 08, 2026, the company has 14 employees.
In which sector is Equillium located?▼
Equillium operates in the Health & Wellness sector.
When did Equillium complete a stock split?▼
Equillium has not had any recent stock splits.
Where is Equillium headquartered?▼
Equillium is headquartered in LA JOLLA, United States.